World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
109
Citations
54429
World Ranking
5694
National Ranking
225

Overview

Amit M. Oza is affiliated with the Princess Margaret Cancer Centre in Canada. Their research primarily focuses on the fields of Medicine, with an emphasis on Oncology, Reproductive Medicine, Molecular Biology, Genetics, and Obstetrics and Gynecology. The scientist has contributed extensively to the understanding and treatment of ovarian cancer and related gynecologic malignancies.

The main topics covered in their work include:

  • Ovarian cancer diagnosis and treatment
  • PARP inhibition in cancer therapy
  • BRCA gene mutations in cancer
  • Endometrial and Cervical Cancer Treatments
  • Cancer Genomics and Diagnostics
  • Toxin Mechanisms and Immunotoxins
  • Genetic factors in colorectal cancer

Amit M. Oza has published research in several frequent venues, which include:

  • Journal of Clinical Oncology
  • Gynecologic Oncology
  • International Journal of Gynecological Cancer
  • Clinical Cancer Research
  • Annals of Oncology

Their recent papers are:

  • Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial (2022, Journal of Clinical Oncology)
  • Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial (2021, The Lancet Oncology)
  • Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study (2021, The Lancet Oncology)
  • Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I (2021, Annals of Oncology)
  • Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial (2021, The Lancet Oncology)

Frequent co-authors of Amit M. Oza include:

  • Stéphanie Lheureux
  • Ana Oaknin
  • Nicoletta Colombo
  • Neesha C. Dhani
  • Valerie Bowering

Best Publications

  • A phase 3 trial of bevacizumab in ovarian cancer.

    Timothy J Perren;Ann Marie Swart;Jacobus Pfisterer;Jonathan A Ledermann

  • Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Kathleen Moore;Nicoletta Colombo;Giovanni Scambia;Byoung Gie Kim

  • Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial

    Camilla Zimmermann;Nadia Swami;Monika Krzyzanowska;Monika Krzyzanowska;Breffni Hannon;Breffni Hannon

  • Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

    Eric Pujade-Lauraine;Jonathan A Ledermann;Frédéric Selle;Val Gebski

  • Rethinking ovarian cancer: recommendations for improving outcomes

    Sebastian Vaughan;Jermaine I. Coward;Robert C. Bast;Andy Berchuck

  • Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

    Robert L Coleman;Amit M Oza;Domenica Lorusso;Carol Aghajanian

  • Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

    Karen A Gelmon;Marc Tischkowitz;Helen Mackay;Kenneth Swenerton

  • Epithelial Ovarian Cancer

    Stephanie Lheureux;Charlie Gourley;Ignace Vergote;Amit M Oza

  • Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

    Elizabeth M Swisher;Kevin K Lin;Amit M Oza;Clare L Scott

  • Epithelial ovarian cancer: Evolution of management in the era of precision medicine

    Stephanie Lheureux;Stephanie Lheureux;Marsela Braunstein;Amit M. Oza;Amit M. Oza

  • Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial

    Mace L. Rothenberg;Amit M. Oza;Robert H. Bigelow;Jordan D. Berlin

  • Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

    Amit M. Oza;Adrian D. Cook;Jacobus Pfisterer;Andrew Embleton

  • Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia

    Agustin A. Garcia;Hal Hirte;Gini Fleming;Dongyun Yang

  • The Statins as Anticancer Agents

    Kelvin K W Chan;Amit M Oza;Lillian L Siu

  • Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

    Amit M Oza;David Cibula;Ana Oaknin Benzaquen;Christopher Poole

  • 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

    A du Bois;M Quinn;T Thigpen;J Vermorken

  • Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study

    Weiva Sieh;Martin Köbel;Teri A Longacre;David D Bowtell;David D Bowtell

  • Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

    Kathleen N Moore;Angeles Alvarez Secord;Melissa A Geller;David Scott Miller

  • Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors

    M. Moore;H. W. Hirte;L. Siu;A. Oza

  • Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II Trial

    Jennifer J. Knox;David Hedley;Amit Oza;Ron Feld

Frequent Co-Authors

Ana Oaknin
Ana Oaknin Vall d'Hebron Hospital Universitari
Nicoletta Colombo
Nicoletta Colombo University of Milano-Bicocca
David M. O'Malley
David M. O'Malley The Ohio State University
Giovanni Scambia
Giovanni Scambia Catholic University of the Sacred Heart
Michael Friedlander
Michael Friedlander University of New South Wales
Robert L. Coleman
Robert L. Coleman The University of Texas MD Anderson Cancer Center
Jonathan A. Ledermann
Jonathan A. Ledermann University College London
Elizabeth M. Swisher
Elizabeth M. Swisher University of Washington
Lillian L. Siu
Lillian L. Siu University of Toronto
Carol Aghajanian
Carol Aghajanian Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring career opportunities in medicine goes beyond earning an MD. Many professionals pursue alternative or complementary pathways that expand their expertise and open doors to leadership and specialized roles in healthcare.

For those interested in healthcare management, accreditation and networking opportunities are key when selecting programs. Consider reviewing the best online mha programs if you’re aiming for a role in hospital or clinic administration. Budget-conscious students may also want to look at the cheapest online master degree in healthcare administration to maximize value while gaining critical skills.

Nurses seeking to advance their clinical expertise can explore the cheapest online bsn to dnp programs, which offer a flexible route to a terminal degree in nursing practice. If pharmacy is your area of interest, the best online pharmacy school programs provide a pathway to a rewarding career in pharmaceutical science.

Online health degrees offer flexible schedules, lower costs, and a breadth of career options, helping you tailor your education to your goals in the medical field.

Best Scientists Citing Amit M. Oza

Trending Scientists

Recently Published Articles